Stereotaxis, Inc. 2010 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Stereotaxis, Inc.
Reporting Period: Fiscal year ended December 31, 2010
Business Overview: Stereotaxis designs, manufactures, and markets the Niobe® system, an advanced cardiology instrument control system that uses magnetic fields to remotely navigate catheters and guidewires for treating arrhythmias and coronary artery disease. The company also markets the Odyssey® Enterprise Solution for lab information management. The company operates as a single segment with sales in the U.S. and internationally.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenue | $54.05 million | $51.15 million |
| Gross Margin | $38.49 million (71.2%) | $34.13 million (66.7%) |
| Operating Loss | $(18.96 million) | $(23.84 million) |
| Net Loss | $(19.92 million) | $(27.49 million) |
| Cash and Equivalents | $35.25 million | $30.55 million |
| Working Capital | $12.40 million | $12.88 million |
| Total Debt (Current + Long-term) | $28.89 million | $23.68 million |
| Backlog (as of Dec 31, 2010) | $43 million | $37 million |
Note: The company reported a net loss per share of $(0.39) for 2010 compared to $(0.63) for 2009.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 6% to $54.05 million. This was driven by a 24% increase in recurring revenue (disposables, service, and accessories) to $23.0 million, partially offset by a 5% decrease in system sales revenue to $31.1 million due to fewer Niobe system installations (21 units in 2010 vs. 25 in 2009).
- Margin Expansion: Gross margin improved to 71.2% from 66.7% in 2009. Cost of revenue decreased 9% due to lower raw material costs and reduced software upgrade expenses.
- Expense Management: Research and Development (R&D) expenses decreased 14% to $12.2 million. Sales and Marketing expenses increased 5% to $30.2 million primarily due to increased headcount. General and Administrative expenses remained flat at $15.0 million.
- Accounting Changes: The adoption of ASU 2009-13 allowed for earlier revenue recognition on certain Odyssey systems, contributing approximately $3.3 million in additional revenue and $1.7 million in gross margin for 2010.
Guidance, Outlook, and Risks
- Liquidity and Capital Resources: The company expects to incur additional losses in 2011. Management believes existing cash, cash equivalents, and borrowing facilities (including a $30 million revolving line of credit with $7.5 million available capacity) are sufficient to fund operations for the next 12 months.
- Outlook: The company anticipates continued growth in recurring revenue from its installed base. However, system sales remain subject to long sales cycles and hospital construction timelines.
- Key Risks:
- Profitability: The company has incurred cumulative net losses of approximately $343 million since inception and may never achieve profitability.
- Collaboration Dependence: Significant revenue and product development rely on strategic alliances with Siemens, Philips, and Biosense Webster. Delays or failures in these partnerships could materially impact operations.
- Regulatory and Reimbursement: Future revenue depends on maintaining FDA/CE Mark approvals and third-party payer reimbursement for procedures using the Niobe system.
- Supply Chain: Reliance on single-source suppliers for critical components (e.g., magnets) poses a risk to manufacturing continuity.
Investor Verification Checklist
- Backlog Conversion: Verify the rate at which the $43 million backlog is converted to recognized revenue, noting that 67% was expected to be recognized in 2011.
- Recurring Revenue Trend: Monitor the growth of recurring revenue (disposables and services), which now comprises 42% of total revenue, as a key indicator of installed base health.
- Debt Covenants: Review compliance with "tangible net worth" and liquidity covenants in the revolving credit agreement and the Biosense Webster advance agreement.
- Collaboration Status: Assess the status of the Biosense Webster alliance, specifically the recoupment of the $18 million advance and the development of next-generation catheters.
- Cash Burn Rate: Track operating cash flow usage, which was $18.9 million in 2010, against available liquidity to determine the runway for operations without additional financing.